A Phase II Trial of ZD1839 (IRESSA®) in Both Patients with Chemosensitive and Chemorefractory Relapsed Neuroendocrine Cancers

Abstracts/Posters/Presentations:

• Moore, A., Estes, D., Govindan, R., Vinson, J., Calley, C., Yu, M., Einhorn, L., Hanna, N.. A Phase II Trial of Gefitinib (Iressa) in Patients With Chemosensitive and Chemorefractory Relapsed Neuroendocrine Cancers. A Hoosier Oncology Group Trial LUN02-29. Presented as part of the Scientific Program in the Lung Cancer General Poster Session 2005 Annual Meeting of the American Society of Clinical Oncology. May 13 – 17, 2005 in Orlando, FL, USA.